Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab

Clinical Colorectal Cancer

Volumn 6, Issue 6, 2007, Pages 447-449

  Gupta, Bhavna ^a   LeVea, Charles ^a   Litwin, Alan ^a   Fakih, Marwan G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Bilirubin; Hepatic toxicity; Steatosis

Indexed keywords

ATORVASTATIN; BEVACIZUMAB; BIOCHEMICAL MARKER; CETUXIMAB; COLESTYRAMINE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LANSOPRAZOLE; METOPROLOL; OXALIPLATIN; PREDNISONE; QUINAPRIL; URSODEOXYCHOLIC ACID;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CHOLESTASIS; COLON CANCER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ENTERITIS; GENETIC POLYMORPHISM; GENOTYPE; HEMICOLECTOMY; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER TOXICITY; LOADING DRUG DOSE; MALE; MEDICAL CARE; METASTASIS; NEUTROPENIA; SIDE EFFECT; SINGLE DRUG DOSE; TOTAL PARENTERAL NUTRITION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 34247533780     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.015     Document Type: Article

References (13)

1. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinoecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
5. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807-814.
6. Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmcol Ther 2002; 72:265-275.
7. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-2072.
8. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
9. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:3061-3068.
10. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
11. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15:1502-1510.
12. Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303-4312.
13. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8:1049-1051.